Health
Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®.iKEYTRUDA (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhib
About this update from Agilent Technologies, Inc.
[{"type":"text","content":"BURLINGTON, N.C., April 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®.i KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer.ii","length":682,"tagName":"p"},{"type":"image","alt":"Labcorp Logo (PRNewsfoto/Labcorp)","displaySize":"","headline":null,"caption":"Labcorp Logo (PRNewsfoto/Labcorp)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":107,"url":"https://media.zenfs.com/en/prnewswire.com/dfb2a169dcf74a375ce32bd7ba958549"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eGbvv5TPrHsEYJVmjXqFCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4OQ--/https://media.zenfs.com/en/prnewswire.com/dfb2a169dcf74a375ce32bd7ba958549","width":400,"height":107}},"href":"https://mma.prnewswire.com/media/2044800/Labcorp_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Helping Patients Access Critical New Treatment OptionsApproximately 80% of individuals with ovarian cancer experience recurrence after initial therapy, and many develop resistance to platinum-based chemotherapy, leading to limited treatment options and poor survival outcomes. The approval of KEYTRUDA and KEYTRUDA QLEX in this setting introduces meaningful new treatment options that have been found to reduce the risk of disease progression and improve overall survival.iii Labcorp's nationwide availability of PD-L1 IHC 22C3 pharmDx enables clinicians to quickly identify patients who may benefit from these newly approved treatments.","length":642,"tagName":"p"},{"type":"text","content":""Platinum-resistant ovarian cancer is incurable, and current treatment options offer limited and short-lived benefits for patients—making it one of the most challenging forms of the disease to treat," said Dr. Marcia Eisenberg, Ph.D., chief scientific officer at Labcorp. "By making t...